Severe immune-related adverse events in the treatment with Pembrolizumab for a patient with ampullar carcinoma
- VernacularTitle:Pembrolizumab治疗十二指肠壶腹部癌过程中引发严重免疫相关不良反应
- Author:
Wei WANG
1
;
Ze XING
;
hua Ran CAO
;
cheng Hai YAN
;
yun Wu SU
Author Information
- Keywords: duodenal neoplasms; ampullar carcinoma; programmed death receptor-1; pembrolizumab; immune-related injury
- From: Tianjin Medical Journal 2017;45(11):1215-1217
- CountryChina
- Language:Chinese
- Abstract: Programmed death receptor-1 inhibitor pembrolizumab can restore the function of T cell activity and enhance the anti-tumor immune response by inhibiting the binding of PD-1 to its ligand PD-L1 and blocking the negative regulation of signal pathway. The activated T cells may cause immune-mediated adverse events in the process of anti-tumor. This article reported the severe immune related adverse effects induced by PD-1 inhibitor, pembrolizumab, in a patient with advanced ampullar carcinoma. The patient eventually died due to liver injury, leukocytosis,thrombocytopenia,and disseminated intravascular coagulation (DIC). This article reviewed the diagnosis and treatment of the patient, and reviewed the relevant literatures.
